If you could rank every longevity intervention by the quality of evidence behind it, you’d get a ladder. This guide is that ladder — an honest scorecard of the most popular interventions, from the ones with decades of human data to the ones that are currently hopes with funding.
The method is simple, and it’s the same one we use internally: how to read a longevity study applied to each intervention. Human evidence beats animal evidence. Replicated results beat single studies. Real outcomes beat surrogate ones.
Tier 1 — Decades of human evidence
These are the levers with the strongest support. None of them are exciting; all of them are real.
- Physical activity. 150 minutes of moderate exercise weekly is associated with reduced all-cause mortality in multiple large cohort studies spanning decades. Strength training specifically preserves muscle and function into old age.
- Sleep. Consistent, sufficient sleep is tied to metabolic, cardiovascular, cognitive, and immune outcomes across the literature. Poor sleep is one of the few “inputs” with near-universal effect.
- Diet quality. Whole-food patterns with adequate protein and limited ultra-processed food are consistently associated with better healthspan. The specific “best diet” debate is far less important than the direction.
- Not smoking, moderating alcohol. The baseline every other intervention builds on.
Tier 2 — Strong but conditional
These work under specific conditions, and the conditions matter.
- Time-restricted eating. Human trials show modest metabolic benefits — real, but smaller than the popular claims. It appears to work partly because it reduces total intake. If it doesn’t suit you, skipping it costs you little.
- Vitamin D. Correcting a genuine deficiency is clearly beneficial; raising already-normal levels is not. Test first, supplement if low, re-test.
- Protein intake. Older adults and athletes often under-eat protein relative to muscle needs. Meeting a target (roughly 1.2–1.6 g/kg for many older adults) supports muscle maintenance.
- Omega-3s. Solid evidence for cardiovascular risk reduction in people with elevated triglycerides; the case for “everyone should take them” is weaker than the marketing.
Tier 3 — Promising, still under study
These have mechanistic rationales and some data — but the honest summary is “we don’t know yet.”
- Metformin and rapamycin. Both have compelling biology and animal evidence, and both are being studied in human trials. Neither is approved for longevity, and neither should be taken for it outside of a clinical trial.
- NAD+ precursors (NMN, NR). Levels decline with age and supplementation restores them — but restoring a molecule is not the same as restoring health. Human outcome data remains thin.
- Senolytics. Clearing senescent cells works in animal models. Human trials are early. The safety questions — especially which cells to clear and when — are far from answered.
Tier 4 — Currently unproven
The supplement and gadget market is full of these. They may work someday. They may not. Right now, the evidence gap is the product.
- Most “anti-aging” supplement stacks. If the label lists a dozen compounds with vague “pathway” claims, you’re paying for a story, not data.
- “Biological age” consumer tests. Research tools, not personal health verdicts — we explain why in our guide to epigenetic clocks.
- Red-light panels, PEMF, and similar devices. The object feels scientific. The evidence for general longevity benefit does not match the price tag.
The hierarchy in one sentence
Spend your effort (and money) from the top down: fix the foundations first, treat tier 2 as optional levers, and treat anything below tier 2 as an experiment — with your eyes open.
Bottom line: The interventions with the most evidence are the least glamorous. That’s not a marketing failure — it’s a signal about where the science actually stands.
Not medical advice. This guide rates the evidence behind popular interventions; it is not a recommendation to take, stop, or change any treatment. Always consult qualified healthcare professionals.